PDCD1 and metabolic dysfunction-associated steatotic liver disease: The synergistic antitumor effect of METTL3 knockout plus anti-PD-1 treatment was further verified in a second orthotopic NAFLD-HCC mouse model using RIL-175 cells (Figures S4A–S4C).